Silexion Therapeutics (NASDAQ:SLXN) Shares Down 7.6% – Time to Sell?

Silexion Therapeutics Corp (NASDAQ:SLXN)’s share price was down 7.6% during mid-day trading on Friday . The stock traded as low as $2.76 and last traded at $2.81. Approximately 24,536 shares traded hands during trading, a decline of 60% from the average daily volume of 60,816 shares. The stock had previously closed at $3.04.

Analyst Ratings Changes

SLXN has been the subject of several research reports. Wall Street Zen upgraded shares of Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Silexion Therapeutics has an average rating of “Hold” and a consensus price target of $75.00.

Silexion Therapeutics Price Performance

The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97. The stock has a market capitalization of $8.80 million, a price-to-earnings ratio of -0.25 and a beta of -0.06. The business’s fifty day moving average price is $3.12 and its 200-day moving average price is $7.26.

Silexion Therapeutics (NASDAQ:SLXN) last announced its earnings results on Wednesday, November 12th. The company reported ($2.88) EPS for the quarter, beating the consensus estimate of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.